US 12,453,709 B2
Compositions and methods for treating autism
Steven Hoffman, Mahwah, NJ (US); and John Rothman, Lebanon, NJ (US)
Assigned to YAMO PHARMACEUTICALS LLC, New York, NY (US)
Filed by Yamo Pharmaceuticals LLC, New York, NY (US)
Filed on Apr. 24, 2023, as Appl. No. 18/305,826.
Application 18/305,826 is a continuation of application No. 17/067,949, filed on Oct. 12, 2020, granted, now 11,633,372.
Application 17/067,949 is a continuation of application No. 16/040,405, filed on Jul. 19, 2018, granted, now 10,813,901, issued on Oct. 27, 2020.
Application 16/040,405 is a continuation in part of application No. 15/695,327, filed on Sep. 5, 2017, granted, now 10,085,959, issued on Oct. 2, 2018.
Application 15/695,327 is a continuation of application No. 15/138,733, filed on Apr. 26, 2016, granted, now 9,757,348, issued on Sep. 12, 2017.
Application 15/138,733 is a continuation of application No. 14/520,116, filed on Oct. 21, 2014, granted, now 9,326,962, issued on May 3, 2016.
Application 14/520,116 is a continuation in part of application No. 14/062,165, filed on Oct. 24, 2013, abandoned.
Claims priority of provisional application 61/894,261, filed on Oct. 22, 2013.
Prior Publication US 2023/0310358 A1, Oct. 5, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/198 (2006.01); A61K 9/00 (2006.01); A61K 9/48 (2006.01); A61K 31/19 (2006.01); A61K 31/4166 (2006.01); A61K 31/55 (2006.01); A61K 45/06 (2006.01)
CPC A61K 31/198 (2013.01) [A61K 9/0019 (2013.01); A61K 9/0053 (2013.01); A61K 9/48 (2013.01); A61K 31/19 (2013.01); A61K 31/4166 (2013.01); A61K 31/55 (2013.01); A61K 45/06 (2013.01); A61K 2300/00 (2013.01)] 21 Claims
 
1. A method for treating a disorder that is Asperger's Disorder (Asperger Syndrome) or Social Communication Disorder in a human in need thereof, comprising:
administering a daily amount of about 50 mg (w/w) to about 1500 mg (w/w) of α-methyl-DL-tyrosine for a term of at least one week.